Home
Line Bjørge's picture

Line Bjørge

Professor
  • E-mailLine.Bjorge@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2020. Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers. 1-18.
  • 2020. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • 2020. Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential. Experimental Cell Research. 1-9.
  • 2020. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model . EBioMedicine. 1-12.
  • 2020. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine. 1-13.
  • 2019. Shared heritability and functional enrichment across six solid cancers. Nature Communications. 1-23.
  • 2019. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. The Lancet Oncology. 1409-1419.
  • 2019. Metabolomics identifies placental dysfunction and confirms Flt-1 (FMS-like tyrosine kinase receptor 1) biomarker specificity. Hypertension. 1136-1143.
  • 2019. Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. Scientific Reports. 1-11.
  • 2019. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk. Cancer Research. 505-517.
  • 2019. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. International Journal of Cancer. 1-10.
  • 2019. Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American women. Cancer Medicine. 2503-2513.
  • 2019. Concentration of fibrin monomer in pregnancy and during the postpartum period. Annals of Clinical Biochemistry. 1-9.
  • 2019. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. The Lancet Oncology. 1171-1182.
  • 2019. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemotherapy and Pharmacology. 791-798.
  • 2018. rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. International Journal of Molecular Sciences. 1-13.
  • 2018. Within-subject biological variation of activated partial thromboplastin time, prothrombin time, fibrinogen, factor VIII and von Willebrand factor in pregnant women. Clinical Chemistry and Laboratory Medicine. 1-12.
  • 2018. White blood cell BRCA1 promoter methylation status and ovarian cancer risk. Annals of Internal Medicine. 326-334.
  • 2018. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLOS ONE. 1-13.
  • 2018. Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. Journal of Magnetic Resonance Imaging. 1637-1647.
  • 2018. Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica. 1010-1017.
  • 2018. Placental inflammation in pre-eclampsia by Nod-like receptor protein (NLRP)3 inflammasome activation in trophoblasts. Clinical and Experimental Immunology. 84-94.
  • 2018. Placental inflammation by HMGB1 activation of TLR4 at the syncytium. Placenta. 53-61.
  • 2018. High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 1-10.
  • 2018. Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: An International Journal of Obstetrics and Gynaecology. 1695-1703.
  • 2018. Adult height is associated with increased risk of ovarian cancer: A Mendelian randomisation study. British Journal of Cancer. 1123-1129.
  • 2018. A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk. Cancer Research. 5419-5430.
  • 2017. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. OncoTarget. 106989-107001.
  • 2017. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • 2017. Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study. PLOS ONE. 1-12.
  • 2017. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica. 497-505.
  • 2017. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics. 680-691.
  • 2017. Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer. 840-847.
  • 2017. C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease. PLOS ONE. 1-12.
  • 2017. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. OncoTarget. 64670-64684.
  • 2017. A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway. Acta Obstetricia et Gynecologica Scandinavica. 1162-1169.
  • 2016. Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • 2016. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • 2016. The antihypertensive MTHFR gene polymorphism rs17367504-G is a possible novel protective locus for preeclampsia. Journal of Hypertension. 132-139.
  • 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLOS ONE.
  • 2016. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology. 78-89.
  • 2016. PALB2, CHEK2 and ATM rare variants and cancer risk: Data from COGS. Journal of Medical Genetics. 800-811.
  • 2016. Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: Results from a large-scale collaboration. OncoTarget. 72381-72394.
  • 2016. Implementing medical abortion with mifepristone and misoprostol in Norway 1998-2013. International Journal of Epidemiology.
  • 2016. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications.
  • 2016. Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer. Cancer Epidemiology, Biomarkers and Prevention. 61-67.
  • 2016. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute. 1-10.
  • 2016. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. OncoTarget. 69097-69110.
  • 2016. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics. 741-756.
  • 2016. Adverse pregnancy outcomes after treatment for cervical intraepithelial neoplasia. Obstetrics and Gynecology. 1265-1273.
  • 2016. Adult body-mass index and ovarian cancer risk by subtype: A Mendelian randomization study. International Journal of Epidemiology. 884-895.
  • 2015. Tumour apparent diffusion coefficient is associated with depth of myometrial invasion and is negatively correlated to tumour volume in endometrial carcinomas. Clinical Radiology. 487-494.
  • 2015. The Norwegian preeclampsia family cohort study: a new resource for investigating genetic aspects and heritability of preeclampsia and related phenotypes. BMC Pregnancy and Childbirth. 1-12.
  • 2015. Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics. 5955-5964.
  • 2015. Refined phenotyping identifies links between preeclampsia and related diseases in a Norwegian preeclampsia family cohort. Journal of Hypertension. 2294-2302.
  • 2015. Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. International Journal of Gynecological Cancer. 459-466.
  • 2015. Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 1574-1584.
  • 2015. Metabolic tumor volume on 18F-FDG PET/CT improves preoperative identification of high-risk endometrial carcinoma patients. Journal of Nuclear Medicine. 1191-1198.
  • 2015. Metabolic profiles of placenta in preeclampsia using HR-MAS MRS metabolomics. Placenta. 1455-1462.
  • 2015. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics. 164-171.
  • 2015. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics. 888-897.
  • 2015. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology. 542-548.
  • 2015. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology. 689-697.
  • 2015. Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLOS ONE.
  • 2015. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications.
  • 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • 2014. Medical abortion with mifepristone and home administration of misoprostol up to 63 days' gestation. Acta Obstetricia et Gynecologica Scandinavica. 647-653.
  • 2014. Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
  • 2014. Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. British Journal of Cancer. 107-114.
  • 2014. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics. 481-497.
  • 2014. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLOS ONE.
  • 2014. Consortium analysis of diet-gene interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition & Food Research. 2023-2035.
  • 2013. Validity of the diagnosis of pre-eclampsia in the Medical Birth Registry of Norway. Acta Obstetricia et Gynecologica Scandinavica. 943-950.
  • 2013. Validity of pre-eclampsia diagnosis in Medical Birth Registry of Norway. Acta Obstetricia et Gynecologica Scandinavica. 243-950.
  • 2013. Menstrual Cycle and Respiratory Symptoms in a General Nordic-Baltic Population. American Journal of Respiratory and Critical Care Medicine. 366-373.
  • 2013. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. European Radiology. 2916-2925.
  • 2012. Pregnancy outcomes after paternal radiofrequency field exposure aboard fast patrol boats. Journal of Occupational and Environmental Medicine. 431-438.
  • 2012. No effects of MRI scan on male reproduction hormones. Reproductive Toxicology. 133-139.
  • 2012. Er det mulig å få pålitelig kunnskap om psykiske senvirkninger etter provosert abort? Tidsskrift for Den norske legeforening. 1450-1452.
  • 2011. Increased endoplasmic reticulum stress in decidual tissue from pregnancies complicated by fetal growth restriction with and without pre-eclampsia. Placenta. 823-829.
  • 2011. Identification of ACOX2 as a shared genetic risk factor for preeclampsia and cardiovascular disease. European Journal of Human Genetics. 796-800.
  • 2011. A transcriptional profile of the decidua in preeclampsia. American Journal of Obstetrics and Gynecology. 84, e1-84, e27.
  • 2010. STOX2 but not STOX1 is differently expressed in preeclampstic decidua from Norwegian women: data from the Second Nord-Trondelag Health Study. Molecular human reproduction. 960-968.
  • 2010. Medical Abortion at 63 to 90 Days of Gestation. Obstetrics and Gynecology. 962-968.
  • 2010. Matrix Metalloproteinase 1 in Pre-eclampsia and Fetal Growth Restriction: Reduced Gene Expression in Decidual Tissue and Protein Expression in Extravillous Trophoblasts. Placenta. 615-620.
  • 2009. Oral contraception, body mass index, and asthma: A cross-sectional Nordic-Baltic population survey. Journal of Allergy and Clinical Immunology. 391-397.
  • 2008. Whole-genome microarray and targeted placental analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PIGF) from pre-eclamptic and small-for-gegstational-age pregnancies. Journal of Maternal-Fetal & Neonatal Medicine. 158-165.
  • 2006. Placental expression of glycophosphatidylinositol (GPI)-anchored proteins in paroxysmal nocturnal haemoglobinuria. Scandinavian Journal of Immunology.
  • 2006. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy. Scandinavian Journal of Immunology. 355-364.
  • 2006. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy. Scandinavian Journal of Immunology. 355-364.
  • 2006. Cardiopulmonary distress during obstetrical anaesthesia: attempts to diagnose amniotic fluid embolism in a case series of suspected allergic anaphylaxis. Acta Anaesthesiologica Scandinavica. 324-330.
  • 2005. Ascitic complement system in ovarian cancer. British Journal of Cancer. 895-905.
Lecture
  • 2019. The NLRP3 inflammasome expression by maternal and fetal cells in the uterine wall and association with preeclampsia development. .
  • 2019. NLRP3 inflammasome expression by maternal and fetal cells in decidua and its association with preeclampsia .
  • 2019. Divergent regulation of decidual oxidative stress response in preeclampsia with and without fetal growth restriction.
  • 2017. Inflammation in preeclampsia by NOD-like receptor protein (NLRP)3 inflammasome activation in trophoblasts.
  • 2017. An inflammatory role for NOD1 in decidua and placenta of normal and preeclamptic pregnancies.
  • 2014. Inflammation in normal and preeclamptic pregnancies.
Academic lecture
  • 2018. Decidual inflammation in normal and preeclamptic pregnancies.
  • 2016. Decidual Nrf2-mediated oxidative stress response in preeclampsia and fetal growth restriction.
  • 2015. The inflammatory role of HMGB1 in preeclampsia.
  • 2013. Preeclampsia and cardiovascular disease - shared causative genetic mechanisms?
  • 2013. Arvelighet av kardiovaskulær sykdom i en familiekohort med økt forekomst av preeklampsi.
  • 2013. A preeclampsia genome-wide linkage scan in Norwegian families.
  • 2011. MEDICAL ABORTION WITH HOME ADMINISTRATION OF MISOPROSTOL UP TO 63 DAYS GESTATION.
  • 2010. Norway: In transition from surgical to medical termination.
  • 2010. Endoplasmic reticulum stress in decidual tissue from pregnancies complicated by pre-eclampsia.
  • 2008. Women's choices: Why do they opt for medical abortion?
Doctoral dissertation
  • 2019. Rethinking Gynecological High- Grade Serous Carcinoma. Portraying the p53 isoform landscape and development of a new preclinical for optical imaging in xenograft models.
  • 1996. Complement regulatory proteins in malignancies. -.
Academic chapter/article/Conference paper
  • 2007. Immunologi og reproduksjon. 6 pages.
Abstract
  • 2019. Toll-like receptor 3 expression and activation at the maternal-fetal interface in pregnancy . Clinical medicine (London).
  • 2019. Toll-Like Receptor-3 expression by maternal and fetal cells at the maternal-fetal interface is associated with development of preeclampsia. Pregnancy Hypertension. S15.
  • 2019. The NLRP3 inflammasome expression by maternal and fetal cells in the uterine wall and association with preeclampsia development. Placenta. e15.
  • 2019. Metabolomics identifies placental dysfunction and confirms Flt-1 biomarker specificity. Pregnancy Hypertension. S5.
  • 2019. Divergent regulation of decidual oxidative stress response in preeclampsia with and without fetal growth restriction. Pregnancy Hypertension. S21.
  • 2018. Decidual inflammation in normal and preeclamptic pregnancies. Pregnancy Hypertension. S33-S34.
  • 2017. No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention. 420-424.
  • 2017. Inflammation in preeclampsia by NOD-like receptor protein (NLRP)3 inflammasome activation in trophoblasts. Pregnancy Hypertension. 21.
  • 2017. An inflammatory role for TLR3 in decidua and placenta of normal and preeclamptic pregnancies. Placenta. 278.
  • 2017. An inflammatory role for NOD1 in decidua and placenta of normal and preeclamptic pregnancies. Placenta. 235.
  • 2016. NLRP3 inflammasome expression and activation at the maternal-fetal interface in preeclamptic and healthy pregnancies. Placenta. 88-88.
  • 2015. The inflammatory role of HMGB1 in preeclampsia. Pregnancy Hypertension. 229.
  • 2015. Identifying a novel link between preeclampsia and chronic hypertension in the MTHFR gene using the population based Norwegian HUNT Study. Pregnancy Hypertension. 243-244.
  • 2015. A genetic connection between preeclampsia and chronic hypertension in Norwegian families. Pregnancy Hypertension. 138-139.
  • 2013. PANOBINOSTAT / CARBOPLATIN DELAY POSTSURGICAL RELAPSE OF OVARIAN CARCINOMA IN AN ORTHOTOPIC MOUSE MODEL. International Journal of Gynecological Cancer. 1 pages.
  • 2013. Arvelighet av kardiovaskulær sykdom i en familiekohort med økt forekomst av preeklampsi. Gynekologen. 43-44.
  • 2013. A preeclampsia genome-wide linkage scan in Norwegian families. Pregnancy Hypertension. 64.
  • 2012. Venøs trombose i svangerskapet: Internasjonale retningslinjer blir norske. Gynekologen. 43.
  • 2012. Trender i bruken av medikamentell abort i Noreg. Gynekologen.
  • 2012. Medical abortion with home administration of misoprostol up to 63 days gestation. Acta Obstetricia et Gynecologica Scandinavica. 33-34.
  • 2012. Medical abortion at 9-12 weeks. Acta Obstetricia et Gynecologica Scandinavica. 49-49.
  • 2012. INVESTIGATING GENETIC PREDISPOSITION AND CLINICAL OCCURRENCE OF PREECLAMPSIA AND CARDIOVASCULAR DISEASE THROUGH A FAMILY-BASED DESIGN. Placenta. A82-A82.
  • 2012. HPV-vaksinasjon – er kunnskapsnivået hos norske medisinetstudenter og allmennleger tilstrekkelig høyt? Gynekologen. 43.
  • 2012. Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: Analysis of tumor growth and response to therapy. Acta Obstetricia et Gynecologica Scandinavica. 16-17.
  • 2012. A population and family based study design to investigate genetic predisposition to preeclampsia and cardiovascular disease. The Norwegian Preeclampsia Family Study. Acta Obstetricia et Gynecologica Scandinavica. 135-136.
  • 2011. Establishment of a Norwegian Preeclampsia Family Biobank. Placenta. A85-A85.
  • 2011. Endoplasmic reticulum stress in decidual tissue from pregnancies complicated by pre-eclampsia and fetal growth restriction. Placenta.
  • 2010. Endoplasmatic reticulum stress in decidual tissue from pregnancies complicated with preeclampsia. Hypertension in Pregnancy.
  • 2010. Classification of pre-eclamptic pregnancies in health registries. An evaluation of criteria selected and pregnancies included in the Medical Birth Registry of Norway. Hypertension in Pregnancy.
Poster
  • 2019. What you should know about tumor reductive surgery in advanced ovarian cancer – Clinical recommendations from a patient perspective.
  • 2019. Toll-Like Receptor-3 expression by maternal and fetal cells at the maternal-fetal interface is associated with development of preeclampsia .
  • 2019. Toll-Like Receptor-3 expression by maternal and fetal cells at the maternal-fetal interface is associated with development of preeclampsia.
  • 2019. Metabolomics identifies placental dysfunction and confirms Flt-1 biomarker specificity.
  • 2019. EP889 improved cytoreduction of ovarian cancer using CD24 targeted fluorescence image guided surgery in a preclinical murine model.
  • 2018. TLR3 expression and activation at the maternal-fetal interface in pregnancy.
  • 2018. Inflammation at the uterine wall lining in pregnancy.
  • 2017. Engraftement optimization, charaterization and tumor spread tracking by preclinical imaging in ovarian cancer patiant.
  • 2017. An inflammatory role for TLR3 in decidua and placenta of normal and preeclamptic pregnancies.
  • 2016. Toll-like receptor 3 expression and activation at the maternal-fetal interface in pregnancy.
  • 2016. Nrf2-mediated oxidative stress response at the maternal-fetal interface in preeclampsia and fetal growth restriction.
  • 2016. NLRP3 inflammasome expression and activation at the maternal-fetal interface in preeclamptic and healthy pregnancies.
  • 2015. The inflammatory role of HMGB1 in preeclamptic and normal pregnancies.
  • 2015. The NLRP3 inflammasome in placentas from preeclamptic and healthy pregnancies.
  • 2015. Metabolic profiles of placenta in preeclampsia using HR-MAS MRS metabolomics.
  • 2014. Heritability of cardiovascular diseases in a preeclampsia family cohort.
  • 2014. A genetic connection between preeclampsia and chronic hypertension in Norwegian families.
  • 2013. Panobinostat / carboplatin delay postsurgical relapse of ovarian carcinomas in an orthotopic mouse model.
  • 2013. Histone deacetylase inhibisjon i kombinasjon med platinum i en klinisk relevant ortotopisk musemodel for ovarialcancer.
  • 2013. Heritability of cardiovascular diseases in a preeclampsia family cohort.
  • 2012. A family based cohort study design to investigate genetic predisposition to preeclampsia and cardiovascular disease. The Norwegian Preeclampsia Family Study.
  • 2011. Establishment of a Norwegian Preeclampsia Family Biobank.
  • 2011. Endoplasmic reticulum stress in decidual tissue from pregnancies complicated by pre-eclampsia and fetal growth restriction.
  • 2010. Medical abortion between 9 and 12 weeks gestation. Experiences from a nursing perspective. .
  • 2010. Classification of pre-eclamptic pregnancies in health registries. An evaluation of criteria selected and pregnancies included in the Medical Birth Registry of Norway.
  • 2010. Biobanking of tissue and blood from pregnancies.
Academic literature review
  • 2020. TLR3 expression by maternal and fetal cells at the maternal-fetal interface in normal and preeclamptic pregnancies. 1-11.
  • 2018. Epigenome-based cancer risk prediction: Rationale, opportunities and challenges. 292-309.
  • 2016. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 386-401.
  • 2012. Respiratory health in women: from menarche to menopause. 187-202.
Article in business/trade/industry journal
  • 2014. Antikoagulasjon ved venøs trombose i svangerskapet. Tidsskrift for Den norske legeforening. 926-926.

More information in national current research information system (CRIStin)